EZH2 and breast neoplasm: We previously set out to address this matter by characterizing the mechanisms through which the TBX2 oncogene represses transcription in breast tumours; this uncovered the TBX2-dependent recruitment of a PRC2-like complex to the NDRG1 promoter, containing enzymes such as Enhancer of Zeste Homolog 2 (EZH2) and G9A/GLP, both of which can be targeted pharmacologically (15).